A molecular dynamics study of loop fluctuation in human papillomavirus type 16 virus-like particles: A possible indicator of immunogenicity

Vaccine

Volumn 29, Issue 51, 2011, Pages 9423-9430

  Joshi, Harshad ^a   Cheluvaraja, Srinath ^a   Somogyi, Endre ^a   Brown, Darron R ^b   Ortoleva, Peter ^a  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Computer aided vaccine design; Epitope; FG loop; Human papillomavirus; Immunogenicity; Molecular dynamics; Vaccine; VLP

Indexed keywords

EPITOPE;

ARTICLE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOGENICITY; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; SIMULATION; VIRUS MORPHOLOGY;

ANTIBODIES, VIRAL; CAPSID; CAPSID PROTEINS; EPITOPES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; NEUTRALIZATION TESTS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; UTERINE CERVICAL NEOPLASMS;

EID: 81955165176     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.039     Document Type: Article

References (43)

1. Cervical cancer vaccines. Cancer: principles and practice of oncology 2008, Vol. 22. Lippincott Williams and Wilkins. 8th ed.
2. Zhou J., Sun X.Y., Stenzel D.J., Frazer I.H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly for HPV virion-like particles. Virology 1991, 185:251-257.
3. Hagensee M.E., Yaegashi N., DA G. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993, 67(1):315-322.
4. RC Rose W.B., Reichman R.C., Garcea R.L. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 1993, 67(4):1936-1944.
5. Neeper M.P., Hofmann K.J., KU J. Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisae. Gene 1996, 180(1-2):1-6.
6. Kirnbauer R., Taub J., Greenstone H., Roden R., Dürst M., Gissmann L., et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993, 67:6929-6936.
7. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347:1645-1651.
8. Christensen N.D., Kreider J.W. Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol 1990, 64(7):3151-3156.
9. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121(3):621-632.
10. zur Hausen H. Human papillomavirus & cervical cancer. Indian J Med Res 2009, 130(3).
11. Bishop B., Dasgupta J., Chen X. Structure-based engineering of papillomavirus major capsid L1: controlling particle assembly. Virol J 2007, 4:p3.
12. Bishop B., Dasgupta J., Klein M., Garcea R.L., Christensen N.D., Zhao R., et al. Crystal structures of four types of human papillomavirus L1 capsid proteins. J Biol Chem 2007, 282(43):31803-31811.
13. Roden R., Armstrong A., Haderer P., Christensen N.D., Hubbert N.L., Lowy D.R., et al. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol 1997, 71(8):6247-6252.
14. Senger T., Becker M.R., Schädlich L., Waterboer T., Gissmann L. Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses. J Virol 2009, 83(24):12692-12701.
15. Carter J.J., Wipf G.C., Madeleine M.M., Schwartz S.M., Koutsky L.A., Galloway D.A. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol 2006, 80(10):4664-4672.
16. Roth S.D., Sapp M., Streeck R.E., Selinka H.C. Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33. Virol J 2006, 3(83).
17. White W.I., Wilson S.D., Palmer-Hill F.J., Woods R.M., Ghim S., Hewitt L.A., et al. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 1999, 73(6):4882-4889.
18. Ryding J., Dahlberg L., Wallen-Öhman M., Dillner J. Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. J Gen Virol 2007, 88:792-802.
19. White W.I., Wilson S.D., Bonnez W., Rose R.C., Koenig S., Suzich J.A. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 1998, 72(2):959-964.
20. Christensen N.D., Cladel N.M., Reed C.A., Budgeon L.R., Embers M.E., Skulsky D.M., et al. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 2001, 291(2):324-334.
21. Thönes N., Herreiner A., Schädlich L., Piuko K., Müller M. A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response. J Virol 2008, 82(11):5472-5485.
22. Hanch C., Leo A., Hoekman D. Exploring QSAR-hydrophobic and electronic, and steric constants 1995, American Chemical Society, Washington, DC.
23. Chen X.S., Garcea R.L., Goldberg I., Casini G., Harrison S.C. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 2000, 5(3):557-567.
24. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., et al. The protein data bank. Nucleic Acids Res 2000, 28(1):235-242.
25. Mauricio C.-T., Shepherd C.M., Borelli I.A., Venkataraman S., Lander G., Natarajan P., et al. VIPERdb2: an enhanced and web API enabled relational database for structural virology. Nucleic Acids Res 2009, 37:D436-D442.
26. Humphrey W., Dalke A., Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996, 14(1):33-38.
27. Phillips J.C., Braun R., Wang W., Gumbart J., Tajkhorshid E., Villa E., et al. Scalable molecular dynamics with NAMD. J Comput Chem 2005, 26(16):1781-1802.
28. MacKerell A.D., Bashford D., Bellott M., Dunbrack R.L., Evanseck J.D., Field M.J., et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 1998, 102(18):3586-3616.
29. Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., Klein M.L. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983, 79:926. (10 pages).
30. Feller S.E., Zhang Y., Pastor R.W., Brooks B.R. Constant pressure molecular dynamics simulation: the Langevin piston method. J Chem Phys 1995, 103(11):4613-4621.
31. Schlick T., Skeel R.D., Brunger A.T., Kalé L.V., Board J.A., Hermans J., et al. Algorithmic challenges in computational molecular biophysics. J Comput Phys 1999, 151:9-48.
32. Altis A., Nguyen P.H., Hegger R., Stock G. Dihedral angle principal component analysis of molecular dynamics simulations. J Chem Phys 2007, 126:2444111.
33. Regenmortel M.H.V. What is a B-cell epitope?. Methods Mol Biol 2008, 3-20.
34. Klasse P., Moore J. Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. J Virol 1996, 70(6):3668-3677.
35. Dimmock N.J. Update on the neutralisation of animal viruses. Rev Med Virol 1995, 5(3):165-179.
36. Han T., Marasco W.A. Structural basis of influenza virus neutralization. Ann N Y Acad Sci 2011, 1217:178-190.
37. Burton D.R. Antibodies, viruses and vaccines. Nat Rev Immunol 2002, 2(9):706-713.
38. Wang Z., Christensen N., Schiller J.T., Dillner J. A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol 1997, 78(9):2209-2215.
39. Culp T.D., Spatz C.M., Reed C.A., Christensen N.D. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology 2007, 361(2):435-446.
40. Sadeyen J.R., Tourne S., Shkreli M., Sizaret P.Y., Coursaget P. Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope. Virology 2003, 309(1):32-40.
41. Thönes N., Müller M. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. Virology 2007, 369(2):375-388.
42. Singharoy A., Cheluvaraja S., Ortoleva P.J. Order parameters for macromolecules: application to multiscale simulation. J Chem Phys 2011, 134:044104.
43. Cheluvaraja S., Ortoleva P. Thermal nanostructure: an order parameter/multiscale ensemble approach. J Chem Phys 2010, 132(7):075102.